Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency

• Published in: Clinical and translational science 2024-12, Vol.17 (12), p.e70110-n/a
• Main Authors: Fang, Yu‐Wei, Huang, Chien‐Hsien, Jang, Tsrang‐Neng, Lin, Shih‐Sen, Wang, Jing‐Tong, Huang, Yen‐Ta, Tsai, Ming Hsien
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - pharmacokinetics; Antibiotics; Area Under Curve; Bacteria; Creatinine; Drug dosages; Drug resistance; Female; Half-Life; Healthy Volunteers; Hemodialysis; Humans; Infections; Kidney diseases; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - therapy; Kidneys; Male; Middle Aged; Nervous system; Pharmacokinetics; Plasma; Polymyxin B; Polymyxin B - administration & dosage; Polymyxin B - adverse effects; Polymyxin B - pharmacokinetics; Proteins; Renal Dialysis; Renal function; Renal insufficiency; Renal Insufficiency - complications; Renal Insufficiency - metabolism; Urine; Young Adult
• ISSN: 1752-8054; 1752-8062; 1752-8062
• DOI: 10.1111/cts.70110

Polymyxin B is a viable option for treating antibiotic‐resistant infections; however, current data on its pharmacokinetics, particularly in patients with renal insufficiency, remain inconclusive and necessitates further investigation. To address this gap, we conducted an open‐label, single‐center, single‐dose, parallel‐group pharmacokinetic study. Participants received an intravenous dose of 0.75 mg/kg of polymyxin B and were categorized based on their renal function: those with normal function (creatinine clearance [CLcr] ≥ 90 mL/min), mild renal insufficiency (CLcr 60–89 mL/min), and end‐stage kidney disease patients on intermittent hemodialysis (IHD) (CLcr